Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Viral respiratory infections are common worldwide. It has been suggested that nucleic acid amplification tests, enabling a rapid etiologic diagnosis, may be useful in reducing antibiotic prescriptions rates. The objective of this study was to evaluate if access to a multiplex real-time PCR method would have an impact on antibiotic prescriptions for acute respiratory tract infections (ARTIs), in primary care. Adult patients with respiratory tract infections will be prospectively included. Nasopharyngeal and throat swabs will be analyzed with a multiplex real-time PCR method, targeting 13 viruses and two bacteria. Samples will be collected during the winter season (October-April). Patients will be open-label randomised to receive a rapid result (the following day) or a delayed result (after 10+/-2 days). The investigators are planning to include approximately 400 patients. Prescription of antibiotics will be measured at initial visit as well as at a follow-up visit 10+/-2 days later. Primary endpoint is antibiotic prescription in the acute phase (initial visit) and secondary endpoint antibiotic treatment (ongoing or initiated) at follow-up visit. The hypohesis is that access to a method with the ability of providing a rapid etiologic diagnosis of respiratory infections will affect the use of antibiotics in outpatient care of adult patients with ARTI.


Options:
A: Arm Label: Rapid result; Type: EXPERIMENTAL; Interventions: Procedure: Access to diagnostic test | Arm Label: Delayed result; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Access to diagnostic test; Assigned to Arm(s): Rapid result
B: Arm Label: Ceftaroline fosamil for injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ceftriaxone, Drug: Placebo | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for injection | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone
C: Arm Label: Levofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levofloxacin | Arm Label: CEM-101; Type: EXPERIMENTAL; Interventions: Drug: CEM-101 | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): Levofloxacin | Intervention Type: DRUG; Name: CEM-101; Assigned to Arm(s): CEM-101
D: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection, Drug: Clarithromycin | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Ceftriaxone, Drug: Placebo, Drug: Clarithromycin | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: IV Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Ceftaroline fosamil for Injection, IV Ceftriaxone

Answer: A